Tamuzimod in patients with moderately-to-severely active ulcerative colitis: a multicentre, double-blind, randomised, placebo-controlled, phase 2 induction trial
Bruce E Sands, Remo Panaccione, Geert D’Haens, Stefan Schreiber, Vipul Jairath, Aaron DuVall, Jarosław Kierkuś, Michael Walczak, Snehal Naik, Kye Gilder, Beatriz Lindstrom, Kathleen M. Ogilvie, William J. Sandborn, Séverine Vermeire, David T. Rubin, Laurent Peyrin‐Biroulet, Silvio Danese
Topics & Concepts
MedicineUlcerative colitisPlaceboInternal medicineAdverse effectClinical endpointNauseaGastroenterologyClinical trialRandomized controlled trialIntention-to-treat analysisSurgeryDiseaseAlternative medicinePathologyInflammatory Bowel DiseaseSphingolipid Metabolism and SignalingLiver physiology and pathology